[Development and study of properties of immunoglobulins against Lassa fever]. / Razrabotka i izuchenie svoistv immunoglobulina protiv likhoradki Lassa

A horse may serve the producer of immune antiserum to Lassa virus. Specific immunoglobulin with at least 1:512 titer of virus-neutralizing antibodies to Lassa fever was obtained by alcohol sedimentation after Cohn from the blood serum of immunized horses. The preparation does not differ from heterologous commercial immunoglobulins. Preclinical studies of immunoglobulin to Lassa fever demonstrated its safety and a high specific activity. The agent can be injected both alone and in combination with virasole.

[Development and study of immunoglobulins against Lassa fever]. / Razrabotka i izuchenie svoistv immunoglobulina protiv likhoradki Lassa

The authors validate the use of horses as producers of immune antiserum to Lassa virus. Specific immunoglobulin with at least 1:512 titer of virus neutralizing antibodies to Lassa virus was obtained from the serum of immunized horses by Kohn's alcohol method. The resultant preparation does not differ from the heterologous commercial immunoglobulins. Preclinical studies of immunoglobulin against Lassa virus demonstrated its safety and high specific activity. The strategy of treating with the immunoglobulin alone and in combination with virasol has been experimentally validated.

[Comparative evaluation of test-systems for detection of Venezuelan equine encephalomyelitis virus and variola virus using dot immunoenzyme assay and solid-phase lanthanide immunofluorescent assay]. / Sravnitel'naia otsenka test-sistem dlia opredeleniia virusov venesuél'skogo éntsefalomielita loshadei i ospovaktsiny metodami tochechnogo immunofermentnogo analiza i tverdofaznogo lantanidnogo immunofliuorestsentnogo analiza.

The sensitivity and specificity of 4 experimental test systems for dot enzyme immunoassay (dot-EIA) and solid-phase lanthanide immunofluorescent analysis (SP LIFA) were studied with Venezuelan equine encephalomyelitis (VEE) and variolovaccinia viruses. Test systems for SP LIFA proved to be 25 times more sensitive than those for dot-EIA. The test systems were highly specific and did not react with the heterologous viruses and proteins. Diagnostic agent for detecting VEE virus in dot-EIA was false-positive with Sindbis virus in low dilutions. The first trials of the Russian test systems for dot-EIA and SP LIFA showed that these systems rapidly and reliably detect VEE and variolovaccinia viruses in liquid samples.

[Development and study of the properties of immunoglobulin against Ebola fever]. / Razrabotka i izuchenie svoistv immunoglobulina protiv likhoradki Ebola.

Immunoglobulin to Ebola fever has been for the first time prepared from hyperimmune equine blood sera by alcohol fractionation after Cohn. Preclinical study of the physicochemical and immunobiological properties of immunoglobulin showed that it protects up to 100% Papio hamadryas infected intramuscularly at doses of 110 to 29 LD50 Ebola virus. Scheme for the use of Ebola immunoglobulin has been experimentally validated.

[Preparation of hyperimmune horse serum against Ebola virus]. / Poluchenie giperimmunnoi loshadinoi syborotki protiv virusa Ebola.

Immunization of horses with Ebola virus resulted in production of specific virus-neutralizing antibodies with their maximal level attained on days 28 to 42 postimmunization. Repeated cycles of immunization lead to increase of antibodies titer to 1:4096.

[The isolation of hyperimmune horse serum to the Ebola virus]. / Poluchenie giperimmunnoi loshadinoi syvorotki k virusu Ebola.

Immunization of horses with Ebola virus resulted in the production of specific virus-neutralizing antibody with maximum titres at 28-42 days. Repeated cycles of immunization led to a rise in antibody titres to 1:4096.

[A trial to produce an inactivated Lassa fever vaccine]. / Opyt polucheniia inaktivirovannoi vaktsiny likhoradki Lassa.

A single and double immunization of Papio hamadryas monkeys with an inactivated concentrated purified adsorbed preparation of Lassa virus in doses of 0.5-1.0 and 1.1-2.1 mg by protein, respectively, protected the animals against the development of the disease and occurrence of viremia after an intramuscular challenge with 0.4 PFU dose. Upon aerogenic infection of monkeys protection of 50% of the animals was achieved by a single immunization with the inactivated preparation in a dose 1.1 mg by protein.